Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 3Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 6CNS 5Plasma cell 4Other solid neoplasm 2Other hematologic neoplasm 2Lymphoid 2Gastrointestinal 2Sarcoma 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Ovarian Neoplasms 675Breast Neoplasms 265Uterine Cervical Neoplasms 240Carcinoma, Non-Small-Cell Lung 218Endometrial Neoplasms 201Fallopian Tube Neoplasms 187Carcinoma, Ovarian Epithelial 175Colorectal Neoplasms 164Stomach Neoplasms 152Pancreatic Neoplasms 144Neoplasms 143Melanoma 118Lung Neoplasms 112Carcinoma, Renal Cell 111Triple Negative Breast Neoplasms 108Prostatic Neoplasms 108Squamous Cell Carcinoma of Head and Neck 98Neoplasm Metastasis 96Esophageal Neoplasms 90Urinary Bladder Neoplasms 85Head and Neck Neoplasms 83Sarcoma 69Small Cell Lung Carcinoma 64Carcinoma, Hepatocellular 64Colonic Neoplasms 56Carcinoma, Transitional Cell 49Kidney Neoplasms 41Testicular Neoplasms 38Peritoneal Neoplasms 37Anus Neoplasms 34

Interventions

niraparib 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Disease Progression × Gynecologic × Clear all
NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
31 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡